Literature DB >> 16222783

Modelling and simulation in the development and use of anti-cancer agents: an underused tool?

Ferdinand Rombout1, Leon Aarons, Mats Karlsson, Anthony Man, France Mentré, Peter Nygren, Amy Racine, Hans Schaefer, Jean-Louis Steimer, Iñaki Troconiz, Achiel van Peer.   

Abstract

To help identify the role of modelling and simulation in the development of anti-cancer agents, their main advantages and the obstacles to their rational use, an expert meeting was organized by COST B15. This manuscript presents a synthesis of views expressed at that meeting and indicates future directions. The manuscript also shows some examples where modelling and simulation have proven to be of relevant value in the drug development process for anti-cancer agents.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 16222783     DOI： 10.1007/s10928-005-5910-2

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN： 1567-567X            Impact factor:   2.745


  85 in total

Review 1.  Bcr-Abl inhibition as a modality of CML therapeutics.

Authors:  E Buchdunger; A Matter; B J Druker
Journal:  Biochim Biophys Acta       Date:  2001-08-31

2.  Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit?

Authors:  M J Ratain
Journal:  J Clin Oncol       Date:  1998-07       Impact factor: 44.544

3.  On the relationship between response to treatment and survival time.

Authors:  M Buyse; P Piedbois
Journal:  Stat Med       Date:  1996-12-30       Impact factor: 2.373

Review 4.  Animal models and the molecular pathology of cancer.

Authors:  E A Lovejoy; A R Clarke; D J Harrison
Journal:  J Pathol       Date:  1997-02       Impact factor: 7.996

5.  Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study.

Authors:  B F Cole; R D Gelber; J M Kirkwood; A Goldhirsch; E Barylak; E Borden
Journal:  J Clin Oncol       Date:  1996-10       Impact factor: 44.544

6.  A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials.

Authors:  P F Thall; K E Russell
Journal:  Biometrics       Date:  1998-03       Impact factor: 2.571

7.  Beware of contaminating mouse cells in human xenografts from nude mice.

Authors:  J Yang; A Liu; C Dougherty; X Chen; R Guzman; S Nandi
Journal:  Anticancer Res       Date:  2000 May-Jun       Impact factor: 2.480

Review 8.  The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.

Authors:  J M Brown; A J Giaccia
Journal:  Cancer Res       Date:  1998-04-01       Impact factor: 12.701

Review 9.  STI571: a paradigm of new agents for cancer therapeutics.

Authors:  Michael J Mauro; Michael O'Dwyer; Michael C Heinrich; Brian J Druker
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

10.  Population pharmacokinetic analysis of the major metabolites of capecitabine.

Authors:  R Gieschke; B Reigner; K S Blesch; J L Steimer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-02       Impact factor: 2.745
View more
  6 in total

1.  Semi-mechanistic model for neutropenia after high dose of chemotherapy in breast cancer patients.

Authors:  Amelia Ramon-Lopez; Ricardo Nalda-Molina; Belen Valenzuela; Juan Jose Perez-Ruixo
Journal:  Pharm Res       Date:  2009-06-02       Impact factor: 4.200

2.  Refinement of the population pharmacokinetic model for the monoclonal antibody matuzumab: external model evaluation and simulations.

Authors:  Katharina Kuester; Andreas Kovar; Christian Lüpfert; Brigitte Brockhaus; Charlotte Kloft
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 3.  Population clinical pharmacology of children: general principles.

Authors:  Brian J Anderson; Karel Allegaert; Nicholas H G Holford
Journal:  Eur J Pediatr       Date:  2006-06-29       Impact factor: 3.183

4.  Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy.

Authors:  Christophe Meille; Dominique Barbolosi; Joseph Ciccolini; Gilles Freyer; Athanassios Iliadis
Journal:  Clin Pharmacokinet       Date:  2016-08       Impact factor: 6.447

5.  Modeling NSCLC progression: recent advances and opportunities available.

Authors:  Ahmed Abbas Suleiman; Lucia Nogova; Uwe Fuhr
Journal:  AAPS J       Date:  2013-02-13       Impact factor: 4.009

6.  Optimal chemotherapy for leukemia: a model-based strategy for individualized treatment.

Authors:  Devaraj Jayachandran; Ann E Rundell; Robert E Hannemann; Terry A Vik; Doraiswami Ramkrishna
Journal:  PLoS One       Date:  2014-10-13       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.